Eli Lilly (NYSE:LLY) reported that its phase 3 study of Jaypirca achieved the main goal in treating patients with chronic lymphocytic leukemia (CLL).
According to the company, results from the BRUIN CLL-313 and BRUIN CLL-314 trials will serve as the foundation for applications to expand the drug’s approved use into earlier stages of treatment.
The drugmaker said it intends to submit the findings to regulators worldwide later this year, aiming to broaden Jaypirca’s label.
Eli Lilly also cautioned that overall survival data remain immature, meaning additional follow-up will be required to fully assess the therapy’s long-term benefit for patients.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.